Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sarah Warren

Showing results (61-70 of 82) with videos related to

Pageof 9
Sort By:
Melanoma Research|January 3, 2020
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)Elisa A Rozeman, Warner Prevoo, Mark A J Meier, et al.
The Journal of Infection|June 19, 2022
Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adultsRajeka Lazarus, Christian Taucher, Claire Brown, et al.
Journal for Immunotherapy of Cancer|December 2, 2020
Comprehensive analysis of cutaneous and uveal melanoma liver metastasesEsmee P Hoefsmit, Elisa A Rozeman, Trieu My Van, et al.
NPJ Breast Cancer|May 24, 2022
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trialsSaranya Chumsri, Zhuo Li, Daniel J Serie, et al.
Ebiomedicine|February 10, 2024
Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancerFrancesca Di Modugno, Anna Di Carlo, Sheila Spada, et al.
Nature Medicine|October 10, 2018
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanomaChristian U Blank, Elisa A Rozeman, Lorenzo F Fanchi, et al.
Science Translational Medicine|March 16, 2022
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responsesKunle Odunsi, Feng Qian, Amit A Lugade, et al.
Cell Reports|October 3, 2019
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint TherapyKathrin Renner, Christina Bruss, Annette Schnell, et al.
Nature Medicine|July 24, 2019
A case report of clonal EBV-like memory CD4<sup>+</sup> T cell activation in fatal checkpoint inhibitor-induced encephalitisDouglas B Johnson, Wyatt J McDonnell, Paula I Gonzalez-Ericsson, et al.
Nature Cancer|February 5, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.
Pageof 9

Showing results (61-70 of 82) with videos related to

Sort By:
Pageof 9
Melanoma Research|January 3, 2020
Phase Ib/II trial testing combined radiofrequency ablation and ipilimumab in uveal melanoma (SECIRA-UM)Elisa A Rozeman, Warner Prevoo, Mark A J Meier, et al.
The Journal of Infection|June 19, 2022
Safety and immunogenicity of the inactivated whole-virus adjuvanted COVID-19 vaccine VLA2001: A randomized, dose escalation, double-blind phase 1/2 clinical trial in healthy adultsRajeka Lazarus, Christian Taucher, Claire Brown, et al.
Journal for Immunotherapy of Cancer|December 2, 2020
Comprehensive analysis of cutaneous and uveal melanoma liver metastasesEsmee P Hoefsmit, Elisa A Rozeman, Trieu My Van, et al.
NPJ Breast Cancer|May 24, 2022
Adaptive immune signature in HER2-positive breast cancer in NCCTG (Alliance) N9831 and NeoALTTO trialsSaranya Chumsri, Zhuo Li, Daniel J Serie, et al.
Ebiomedicine|February 10, 2024
Tumoral and stromal hMENA isoforms impact tertiary lymphoid structure localization in lung cancer and predict immune checkpoint blockade response in patients with cancerFrancesca Di Modugno, Anna Di Carlo, Sheila Spada, et al.
Nature Medicine|October 10, 2018
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanomaChristian U Blank, Elisa A Rozeman, Lorenzo F Fanchi, et al.
Science Translational Medicine|March 16, 2022
Metabolic adaptation of ovarian tumors in patients treated with an IDO1 inhibitor constrains antitumor immune responsesKunle Odunsi, Feng Qian, Amit A Lugade, et al.
Cell Reports|October 3, 2019
Restricting Glycolysis Preserves T Cell Effector Functions and Augments Checkpoint TherapyKathrin Renner, Christina Bruss, Annette Schnell, et al.
Nature Medicine|July 24, 2019
A case report of clonal EBV-like memory CD4<sup>+</sup> T cell activation in fatal checkpoint inhibitor-induced encephalitisDouglas B Johnson, Wyatt J McDonnell, Paula I Gonzalez-Ericsson, et al.
Nature Cancer|February 5, 2022
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsetsNina Bhardwaj, Philip A Friedlander, Anna C Pavlick, et al.
Pageof 9